About Naldebain
The world’s 1st seven-day long acting analgesic
Naldebain is indicated for the relief of moderate to severe acute postsurgical pain. It has been used across many different types of operations to relieve pain. The medicine is a sterile oil solution which is suitable for intramuscular injection and from a single injection it can provide pain relief for up to seven days. Naldebain is a synthetic nalbuphine prodrug whose potency is similar to morphine, but without morphine’s risks of addiction and respiratory depression, which makes Naldebain a safer long-acting postoperative analgesic.
Prepared with an improved formula, Naldebain offers prolonged analgesic efficacy and reduces side effects compared to short-acting Nalbuphine.
Naldebain has been proven to have significant post-operative analgesic efficacy. Naldebain patients reported lower pain scores than patients taking a placebo, whether measured 48 hours or 7 days after surgery.
Naldebain reduced the dosage of the rescue medication by 64% in post-operative 0-48 hours and by 43% in 48-168 hours.
The most common treatment emergent adverse events were injection site reaction (27.5%), pyrexia (16.5%), dizziness (6.4%), vomiting (2.8%), nausea (1.8%) and somnolence (0.9%)[1].
The benefits of Naldebain:
Faster ambulation＆Early recovery
Naldebain shows a significantly shorter time to ambulation than other analgesics
Ensure more patients comfort＆safety
The parent compound of Naldebain is nalbuphine which has a dual agonist/antagonist mechanism of action. Nalbuphine is effective at minimizing common opioid AEs such as pruritus, the severity of nausea and vomiting by rebalancing opioid μ and κ neuronal activity[2]. Naldebain also carries less risk of respiratory depression due to its ceiling effect.
